Somatostatin-induced hyperkalemia in a patient on maintenance hemodialysis.
A 65-year-old man, who had been undergoing maintenance hemodialysis for 20 years, suffering from severe postprandial hypotension was studied on 2 consecutive interdialytic days. The drop in blood pressure resulting from the oral administration of 75 g glucose was prevented by the concomitant infusion of somatostatin (350 micrograms/h), but this was accompanied by severe hyperkalemia (7.4 mmol/l). Suppression of insulin by somatostatin may have contributed to the hyperkalemia by impairing cellular potassium uptake. We conclude that although somatostatin prevents postprandial hypotension, hyperkalemia may limit its use in patients with end-stage renal failure.
Sharma
A M
AM
Department of General Internal Medicine and Nephrology, Free University of Berlin, FRG.
Thiede
H M
HM
Keller
F
F
D000368:Aged; D004435:Eating; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced*; D007022:Hypotension / Q000517:prevention & control; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy / Q000628:therapy; D008297:Male; D006435:Renal Dialysis / Q000009:adverse effects*; D013004:Somatostatin / Q000009:adverse effects*
D013004:Somatostatin